

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 August 2023 (17.08.2023)




(10) International Publication Number
WO 2023/154967 A2

(51) International Patent Classification:	63/384,566	21 November 2022 (21.11.2022)	US
<i>G16H 50/20</i> (2018.01) <i>G16B 20/00</i> (2019.01)	63/478,869	06 January 2023 (06.01.2023)	US
(21) International Application Number:	63/478,905	06 January 2023 (06.01.2023)	US
	PCT/US2023/062602		
(22) International Filing Date:			
	14 February 2023 (14.02.2023)		
(25) Filing Language:	English		
(26) Publication Language:	English		
(30) Priority Data:			
63/267,995	14 February 2022 (14.02.2022)	US	
63/364,257	05 May 2022 (05.05.2022)	US	
63/365,410	26 May 2022 (26.05.2022)	US	
63/368,153	11 July 2022 (11.07.2022)	US	
63/393,703	29 July 2022 (29.07.2022)	US	
63/375,355	12 September 2022 (12.09.2022)	US	
63/377,330	27 September 2022 (27.09.2022)	US	
(71) Applicant: VENN BIOSCIENCES CORPORATION			
[US/US]; 2 Tower Place, 5th Floor, South San Francisco, California 94080 (US).			
(72) Inventors: SERIE, Daniel; c/o Venn Biosciences Corporation, 2 Tower Place, 5th Floor, South San Francisco, California 94080 (US). DESAI, Khushbu Yatin; c/o Venn Biosciences Corporation, 2 Tower Place, 5th Floor, South San Francisco, California 94080 (US). HOMMES, Daniel Willem; c/o Venn Biosciences Corporation, 2 Tower Place, 5th Floor, South San Francisco, California 94080 (US). MITCHELL, Alan Nicolas; c/o Venn Biosciences Corporation, 2 Tower Place, 5th Floor, South San Francisco, California 94080 (US). WONG, Maurice Yu; c/o Venn Biosciences Corporation, 2 Tower Place, 5th Floor, South			

(54) Title: DIAGNOSIS OF COLORECTAL CANCER USING TARGETED QUANTIFICATION OF SITE-SPECIFIC PROTEIN GLYCOSYLATION

FIGURE 17



(57) Abstract: The present disclosure encompasses systems, methods, and compositions for diagnosing a subject for a high-grade advanced pre-malignant lesions or colorectal cancer (CRC) disease state by ascertaining the presence of certain one or more glycosylated or aglycosylated peptides in liquid biopsy samples from the subject. Specific embodiments encompass methods of measuring certain one or more glycosylated or aglycosylated peptides in liquid biopsy samples from subjects known to have or suspected of having a high-grade advanced pre-malignant lesions or CRC disease state or subjects undergoing routine health care maintenance for possible presence of a high-grade advanced pre-malignant lesions or CRC disease state. The disclosure provides systems, methods, and compositions to identify subjects at-risk for CRC or high-grade advanced pre-malignant lesions and increases subject colonoscopy compliance, in specific embodiments.

[Continued on next page]

San Francisco, California 94080 (US). **LUI, Mingqi**; 359 Northam Ave, San Carlos, California 94070 (US). **ZHOU, Bo**; 11744 Moorpark Street #M, Los Angeles, California 91604 (US).

(74) **Agent: SISTRUNK, Melissa**; Norton Rose Fulbright US LLP, 555 California Street, Suite 3300, San Francisco, CA 94104 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*